Welcome to our dedicated page for PRF Technologies Ltd. SEC filings (Ticker: PRFX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PainReform Ltd. (PRFX) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a foreign private issuer. PainReform files Form 6-K current reports that furnish press releases, transaction details, financial statements, and other information under the Securities Exchange Act of 1934. These filings document key developments in both its specialty pharmaceutical programs and its DeepSolar energy analytics activities.
Recent 6-K reports include disclosures about PainReform’s majority investment in LayerBio Inc., the company behind the OcuRing™-K sustained-release ocular platform for cataract surgery, along with unaudited pro forma condensed combined financial information and LayerBio’s audited and unaudited financial statements. Other 6-Ks furnish press releases on topics such as acceptance of DeepSolar into the NVIDIA Connect program, the launch of Smart TDD for solar technical due diligence, and the advancement of DeepSolar’s automated reporting engine and DeepSolar Predict forecasting solution.
Filings also cover financial updates, including unaudited condensed financial statements and operating and financial reviews for interim periods, as well as corporate governance matters such as notices and proxy statements for the Annual General Meeting of Shareholders and changes in board composition. Together, these documents form an official record of PainReform’s clinical, commercial, and corporate progress.
On Stock Titan, investors can review these SEC submissions alongside AI-powered summaries that explain the significance of each report. Real-time updates from EDGAR help users follow new Form 6-K filings as they appear, while structured access to exhibits and financial data supports deeper analysis of PainReform’s pharmaceutical pipeline, LayerBio acquisition, and DeepSolar initiatives.
PRF Technologies Ltd. reported that its DeepSolar business unit has signed a solar analytics services agreement with a subsidiary of EDF Group, a global renewable-energy leader. The engagement covers technical due diligence for an operational, utility-scale solar power plant in Israel.
This is DeepSolar’s first commercial due diligence engagement and follows the launch of its Smart TDD service, which analyzes historical and operational plant data. The Smart TDD platform is designed to provide structured, independent technical reviews that help solar asset owners assess condition, performance, and asset-level decision-making.
PRF Technologies Ltd. furnished a report describing a new commercial software-as-a-service agreement for its DeepSolar AI-driven solar analytics platform with Shikun & Binui Energy for the 71 megawatt Satu Mare utility-scale solar plant in Romania. This is positioned as an ongoing commercial deployment rather than a pilot.
DeepSolar will provide continuous analytics and performance monitoring to improve operational visibility, anomaly detection, and data-driven asset management for the plant. PRF highlights this win as part of a broader European expansion, alongside prior DeepSolar pilots and new products such as Smart TDD for technical due diligence and DeepSolar Predict for forecasting, supported by a patent filing in plant-level micro-climate modeling.
PRF Technologies Ltd. is implementing a 1-for-5 reverse share split of its ordinary shares, consolidating every five existing shares into one new share with no par value. The company’s ordinary shares are expected to begin trading on the Nasdaq Capital Market on this adjusted basis on February 6, 2026.
After the reverse split, authorized share capital will consist of 12,000,000 ordinary shares, and issued and outstanding shares will change from 3,915,340 to 783,068, with fractional shares rounded up to the nearest whole share. Exercise prices and share amounts under all outstanding options and warrants will be adjusted proportionately so holders retain equivalent economic value on a post-split basis.
PRF Technologies Ltd. furnished a report highlighting a new step in its energy-technology strategy. The company has filed its first patent application for proprietary methods that model micro-climate conditions at individual solar plants to improve the accuracy of solar energy production forecasts.
The patent application protects core intellectual property behind DeepSolar Predict, PRF’s solar forecasting software platform, and follows the company’s acceptance into the NVIDIA Connect Program. The technology targets a key weakness in conventional solar forecasting, which often relies on broad regional weather data rather than localized conditions that drive actual plant output.
PRF expects that, once commercialized, the DeepSolar Predict platform could help utility-scale solar operators and energy traders optimize dispatch, reduce penalties tied to forecast errors, and enhance financial performance in volatile power markets. This initiative complements PRF’s existing pharmaceutical programs, reflecting a dual focus on extended-release pain therapies and AI-driven renewable energy optimization.
PRF Technologies Ltd., formerly PainReform Ltd., reports that shareholders approved a corporate name change at the January 6, 2026 annual general meeting. The company will continue trading on Nasdaq under the ticker PRFX.
The new name is meant to reflect an evolution from a single-product focus into a diversified innovation platform spanning specialty pharmaceuticals, advanced drug-delivery technologies, and AI-driven renewable-energy analytics. PRF continues to advance its non-opioid postoperative pain therapy PRF-110, while also building its LayerBio ophthalmology platform and DeepSolar AI-driven solar analytics business to pursue growth across healthcare and clean‑energy technology markets.
PainReform Ltd. reported new safety results for OcuRing™-K, a drop-less, sustained-release ocular drug delivery platform being developed with its majority-owned subsidiary LayerBio for use in cataract surgery. A Phase I clinical study in cataract patients and multiple preclinical rabbit studies showed a favorable safety profile, with no treatment-emergent adverse events related to the study drug, no serious adverse events, and no safety issues linked to the drug delivery platform.
In the human study, reported adverse events were in line with expectations for cataract surgery and consistent with patients’ prior eye conditions, while the investigational product and intraocular lens remained properly positioned in all treated eyes. Preclinical studies similarly showed good local tolerability and no tissue abnormalities compared with control. These findings support continued development and IND-enabling work in the United States for OcuRing™-K’s intraocular system, which is designed for targeted, sustained release of NSAIDs, corticosteroids, or other ophthalmic drugs from a single intraoperative application.
PainReform Ltd. reports updated financial information related to its acquisition of LayerBio Inc. The company is acquiring 7,331,378 shares of LayerBio preferred stock, which at closing will represent 51% of LayerBio’s fully diluted share capital under a Preferred Stock Purchase Agreement dated July 8, 2025.
This filing provides three key exhibits: unaudited pro forma condensed combined financial information for PainReform as if the LayerBio acquisition had occurred on January 1, 2024 and on June 30, 2025, audited financial statements of LayerBio for the years ended December 31, 2024 and 2023, and unaudited condensed financial statements of LayerBio for the six months ended June 30, 2025. PainReform notes that the pro forma figures are illustrative only and do not necessarily represent past or future results.
PainReform Ltd. reported that it has scheduled its Annual General Meeting of Shareholders for December 30, 2025, at 3:00 p.m. Israel time. The meeting will take place at the offices of the company’s legal counsel, Amit, Pollak, Matalon & Co., in Tel Aviv, Israel. To support the meeting, PainReform is providing a Notice and Proxy Statement and a Proxy Card for holders of ordinary shares so shareholders can review the agenda and vote their shares in advance or by proxy.
PainReform Ltd. (PRFX) furnished a Form 6-K noting it issued a press release on November 12, 2025 titled “PainReform’s DeepSolar Advances Development of its AI-Driven Automated Reporting Engine for Solar-Asset Analysis.” The release is attached as Exhibit 99.1 and incorporated by reference. The filing provides the exhibit index and signature by Ehud Geller, Executive Chairman and Interim Chief Executive Officer.
PainReform Ltd. (PRFX) filed a Form 6-K noting it issued a press release on November 5, 2025 titled “PainReform’s DeepSolar, Developing ‘DeepSolar Predict’ within the NVIDIA Connect Program, Featured in The Market Link’s ‘Watchlist Interview’ and Announces Progress Toward Pilot Projects.” The press release is attached as Exhibit 99.1 and incorporated by reference.
The report is signed by Ehud Geller, Executive Chairman of the Board and Interim Chief Executive Officer.